NantKwest, Inc. (NASDAQ:NK) Files An 8-K Other Events
Item 8.01 Other Events.
On June 24, 2020, NantKwest, Inc. (the Company) issued a press release announcing the Companys proposed offer and sale of shares of its common stock in an underwritten public offering.
In connection with the proposed offering, the Company has updated its disclosures regarding its business and risk factors. The revised disclosure is filed herewith as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| 99.1 | | Business and Risk Factor disclosure. |
NantKwest, Inc. Exhibit
EX-99.1 2 d947627dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 BUSINESS The following summary highlights selected information about us. This summary is not complete and does not contain all the information that you should consider before investing in our common stock. Before making an investment decision,…
To view the full exhibit click here
About NantKwest, Inc. (NASDAQ:NK)
NantKwest, Inc., formerly Conkwest, Inc., is a biotechnology company engaged in developing targeted direct-acting immunotherapeutic agents for a range of clinical conditions. The Company is focused on harnessing its immune system by using the natural killer (NK) cell to treat cancer, infectious diseases and inflammatory diseases. Its product candidates include activated NK cells (aNK), high-affinity NKs (haNKs) and target activated Natural Killers (taNKs). It develops aNK product candidates for the treatment of virally-induced cancers, such as polyoma virus induced Merkel Cell Carcinoma, Human Papilloma Virus induced cervical, and head and neck cancers, as well as infectious diseases, such as Ebola and other serious viral, fungal and bacterial infections. It also develops haNKs for the treatment of solid tumors, breast cancer, multiple myeloma, lymphoma and colorectal cancer, and taNKs for the treatment of brain cancer, breast cancer, non-hodgkin lymphoma and myelodysplastic syndrome.
